Anthropic Builds Biology Lab For AI

Anthropic is taking artificial intelligence beyond software and into the laboratory, establishing a biology facility in the San Francisco Bay Area as it deepens its push into life sciences. The move brings Claude closer to real-world experimentation and signals a broader ambition to influence how early-stage drug research is carried out.

The lab will allow Anthropic to test whether AI can support biological experiments alongside computer-based research. Over time, the company wants Claude to help direct robotic equipment, analyse results and guide parts of the experimental process, while human researchers remain responsible for oversight and safety.

Anthropic says the programme is still at an early stage, with an initial focus on preclinical research. It is particularly interested in areas that may receive less attention from traditional pharmaceutical companies because of limited commercial returns. Life sciences has also become one of Anthropic’s larger areas of investment, suggesting the company sees scientific research as an important use case for advanced AI.

The expansion creates a notable tension. Anthropic has repeatedly warned that increasingly capable AI systems could be misused in biology, yet it is also developing tools designed to make biological research faster and more effective. That makes safeguards and supervision central to the programme’s credibility.

Anthropic does not plan to run clinical trials, keeping its work focused on the earlier stages of medicine development. The laboratory therefore represents a practical test of how far AI can move from generating ideas to shaping physical experiments. If the approach proves reliable, it could strengthen AI’s role in drug discovery while intensifying debate over automation, scientific accountability and control.